61-Year-Old White Female with a Non-Healing Ulcerated Ankle Mass
Main Article Content
Keywords
Merkel Cell, Ankle Mass, Avelumab, carcinoma
Abstract
Merkel cell carcinoma is a rare cutaneous carcinoma from the tactile Merkel cells. With fewer than half the patients surviving more than one year and fewer than 20% surviving beyond five years. These tumors are rarely suspected until the biopsy results return. Polyoma virus is associated with up to 80% of the tumors. 53% present on the head and neck and 35% present on the extremities while larger lesions are exceedingly rare in either location. Recently, A newly approved drug, Avelumab, has shown tumor response in patients with some patients experiencing complete remission.
References
2. Han S, North J, Canavan T, et al. Merkel cell carcinoma. Hematol Oncol Clin N Amer. 2012; 26:1351 – 1374
3. Goessling, W, Mckee P, Mayer R. Merkel cell carcinoma. J Clin Oncol. 2002; 20:588 – 598.
4. Oram C , Bartus C S, Purcell S. Merkel cell carcinoma: A review. Cutis. 2016 Volume 97, 4 to 90 – 295
5. Wang T, Byrne, P, Et al, Semin Cutan Med Surg. 2011 Mar:30 (1) 48-56
6. Lemos B, Storer B, Lyer J, et al. Pathologic nodal evaluation approves prognostic accuracy and Merkel cell carcinoma; J Amer Acad Derm. 2010; 63(5): 751 – 761.
7. Bobos M, Hytiroglou P, Kostopoulos I, et al. immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. Dermatopathol. 2006; 28:99 – 104.
8. Pearson, J , Meyers, A Skin cancer – Merkel cell carcinoma, Medscape updated March 27, 2017
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.